South Korea Ozempic availability — Samsung Medical Center experience

KevinCompounds said:

If two explanations both fit, the useful question is which one predicts something the other does not.

All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.

SteveThurs said:

Steady state is the thing most people miss.

This is exactly what I could not find anywhere else. I will report back once I have actually tried it.

KevinCompounds said:

If two explanations both fit, the useful question is which one predicts something the other does not.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.

The figures, for anyone assembling their own picture. For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine. Half the figures circulating in this community trace back to a secondary summary that dropped a qualifier.

Moderator note: the sourcing question belongs in the vendor section and has been split out.